Clinical trials: Opioid Use Disorder (OUD)
Opioid-use Disorder, Substance Use Disorders
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) and/or other…
- Trial name
- NCT04197921
- Testing
- Exablate Model 4000 Type 2.0/2.1
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- InSightec
Opioid-use Disorder
Pilot Research on Opioid Use Disorder
This study evaluates the effects of peripheral nerve stimulation on opioid withdrawal, craving, and use in participants with opioid use disorder (OUD) who are initiating treatment with buprenorphine/naloxone.
- Trial name
- PROUD (NCT04244227)
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.
Opioid Use Disorder, Opioid Withdrawal
Suboxone Dispenser for OUD
The goal of this study is to evaluate the usability and acceptability of the Addinex system with patients receiving Suboxone in OUD treatment.
- Trial name
- NCT05790551
- Testing
- Addinex
- Where
- United States
- Sponsor
- Addinex Technologies, Inc.
Opioid-use Disorder, Contingency Management
Usability Testing for the Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden.
- Conditions
- Opioid-use Disorder, Contingency Management, Medication for Opioid-use Disorder
- Trial name
- OARSCM (NCT05159362)
- Testing
- Software Application
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Q2i, LLC
Opioid Use Disorder
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD).
- Trial name
- NCT06538558
- Testing
- Tezampanel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Proniras Corporation
Opioid Use Disorder
iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers
This Phase 1b clinical study is evaluating iSTEP-N, an investigational extended-release implant containing naltrexone, a medication used to block the effects of opioids.
- Trial name
- iSTEP-N (NCT07064564)
- Testing
- Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Akyso Therapeutics, LLC
Opioid Use Disorder (OUD)
A Safety Study of AZD4041 in Healthy Participants
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy male and female adult participants.
- Trial name
- NCT05233085
- Testing
- AZD4041
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Opioid Use Disorder
The Feasibility of VR for OUD
This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their…
- Trial name
- NCT06255119
- Testing
- 3D Therapy Thrive
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- 3D Therapy, LLC
Opioid Use Disorder
Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common…
- Trial name
- OARSCM (NCT05180669)
- Testing
- OARSCM Software Application, MyMAT Software Application
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Q2i, LLC
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Opioid Use Disorder
PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study
The goal of this clinical trial is to learn if it is feasible to use PEX010 for the treatment of opioid use disorder in adults. The study will also assess the safety of PEX010.
- Trial name
- NCT06608459
- Testing
- PEX010-Assisted Therapy
- Volunteers
- 10 people
- Sponsor
- Filament Health Corp.
Addiction
A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of a single day dosing and a separate multiple day dosing of 18-MC HCl administered orally, each part of the study having a different set of healthy…
- Trial name
- NCT04292197
- Testing
- 18-MC Compound
- Where
- Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Definium Therapeutics US, Inc.
Opioid Use Disorder
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
The purpose of this study is to evaluate the efficacy; safety and tolerability of ASP8062 compared with placebo ASP8062 as add-on therapy to buprenorphine/naloxone.
- Trial name
- NCT05062577
- Testing
- ASP8062, buprenorphine/naloxone
- Sponsor
- Astellas Pharma Global Development, Inc.
Opioid Withdrawal (Disorder), Opioid Use Disorder
Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms
This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.
- Trial name
- NCT07079215
- Testing
- Neurostimulation
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Nu Eyne Co., Ltd.
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation